报价延迟最少15分钟:2026/04/27 00:28 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2299 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.58/-0.37
|
|
企业价值
5.84M
|
| 资产负债 |
|
每股账面净值
0.01
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
359.70K
|
|
每股收益
0.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies. |
